<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002624</url>
  </required_header>
  <id_info>
    <org_study_id>CALGB-9335</org_study_id>
    <secondary_id>U10CA031946</secondary_id>
    <secondary_id>CDR0000063987</secondary_id>
    <nct_id>NCT00002624</nct_id>
  </id_info>
  <brief_title>Video-Assisted Surgery Followed by Radiation Therapy in Treating Patients With Stage I Non-small Cell Lung Cancer and Poor Heart and Lung Function</brief_title>
  <official_title>VIDEO ASSISTED WEDGE RESECTION (VAR) AND RADIOTHERAPY FOR HIGH RISK T1 NON-SMALL CELL LUNG CANCER: A PHASE II STUDY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alliance for Clinical Trials in Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Alliance for Clinical Trials in Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Video-assisted surgery followed by radiation therapy may be an effective treatment
      in patients whose poor heart and lung function make them high risk for standard surgery.

      PURPOSE: Phase II trial to study the effectiveness of video-assisted surgery followed by
      radiation therapy in treating patients with stage I non-small cell lung cancer and poor heart
      and lung function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the feasibility of video-assisted thoracoscopic wedge resection (VAR) followed
           by radiotherapy in patients with stage I non-small cell lung cancer and cardiopulmonary
           dysfunction.

        -  Determine the incidence of locoregional recurrence in patients treated with this
           regimen.

        -  Determine the overall and disease-free survival in patients treated with this regimen.

        -  Determine the technical feasibility of ipsilateral lymph node sampling and complete
           resection with VAR in these patients.

        -  Determine the incidence of conversion to open thoracotomy in these patients.

        -  Determine the short- and long-term complications associated with VAR in these patients.

        -  Determine the toxicity of adjuvant radiotherapy after VAR in these patients.

      OUTLINE: This is a multicenter study.

      Patients undergo video-assisted thoracoscopic wedge resection. Surgeons attempt sampling and
      identification of all ipsilateral, mediastinal, and hilar lymph nodes. When accessible, lobar
      lymph nodes must also be sampled. If the tumor margins are positive, further resection of the
      margins must be attempted. Open thoracotomy may be required for technical reasons.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1994</start_date>
  <completion_date type="Actual">August 2005</completion_date>
  <primary_completion_date type="Actual">April 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the feasibility of video-assisted thoracoscopic wedge resection (VAR)</measure>
    <time_frame>Up to 10 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the incidence of locoregional recurrence in patients treated with this regimen</measure>
    <time_frame>Up to 10 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the overall and disease-free survival</measure>
    <time_frame>Up to 10 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the short- and long-term complications associated with VAR in these patients</measure>
    <time_frame>Up to 10 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the technical feasibility of ipsilateral lymph node sampling and complete resection with VAR in these patients</measure>
    <time_frame>Up to 10 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the toxicity of adjuvant radiotherapy after VAR in these patients</measure>
    <time_frame>Up to 10 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Radiotherapy + surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients begin radiotherapy 2-8 weeks postoperatively. Patients with complete resection undergo radiotherapy 5 days a week for 5.6 weeks. Patients with incomplete resection undergo radiotherapy 5 days a week for 6.6 weeks.
Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
    <arm_group_label>Radiotherapy + surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>diagnostic thoracoscopy</intervention_name>
    <arm_group_label>Radiotherapy + surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic thoracoscopy</intervention_name>
    <arm_group_label>Radiotherapy + surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>video-assisted surgery</intervention_name>
    <arm_group_label>Radiotherapy + surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>Radiotherapy + surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Known or suspected, single, peripheral, stage T1 N0 M0 lung tumor

               -  Tumor must not be identifiable by bronchoscopy

                    -  Bronchoscopically visible cancer or bronchial distortions considered related
                       to tumor

               -  Positive cytology by bronchoscopy allowed if no gross abnormality visible

               -  Mediastinoscopy required for nodes greater than 1 cm

               -  No pleural effusions

               -  No metastatic or N2 disease on CT scan

               -  Lesion must be accessible for video-assisted thoracoscopic wedge resection

          -  High cardiopulmonary risk for thoracotomy with at least 1 of the following criteria:

               -  FEV1 less than 40% predicted

               -  DLCO less than 50% predicted

               -  Supplemental oxygen requirement

               -  Chronic PaCO2 greater than 45 mm Hg

               -  Maximum oxygen consumption (VO2 max) less than 15 mL/kg/min

          -  Patients who appear at high risk for non-pulmonary reasons (e.g., patients who are
             elderly or with renal or cardiac failure) may be eligible only if VO2 max or other
             criteria above are met

          -  Eligible for radiotherapy after completion of wedge resection if histologic
             documentation of non-small cell lung cancer, including any of the following subtypes:

               -  Squamous cell carcinoma

               -  Adenocarcinoma

               -  Bronchoalveolar cell

               -  Large cell anaplastic carcinoma

          -  Cytology from bronchial washings and transthoracic needle aspiration not acceptable

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  0-2

        Other:

          -  No other malignancy within the past 5 years except nonmelanomatous skin cancer or
             carcinoma in situ of the cervix

          -  Weight loss no greater than 10% within the past 6 months

        PRIOR CONCURRENT THERAPY:

        Radiotherapy

          -  No prior thoracic irradiation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hani Shennib, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Montreal General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CCOP - Colorado Cancer Research Program, Incorporated</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Stoddard Cancer Center at Iowa Methodist Medical Center</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Cancer Center at Mercy Medical Center-Des Moines</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iowa Lutheran Hospital</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50316-2301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Metro-Minnesota</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midlands Cancer Center at Midlands Community Hospital</name>
      <address>
        <city>Papillion</city>
        <state>Nebraska</state>
        <zip>68128-4157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBCCOP - University of New Mexico HSC</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Cancer Institute at Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drexel University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102-1192</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillman Cancer Center at University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - MainLine Health</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - St. Vincent Hospital Cancer Center, Green Bay</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54307-3453</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Enfermedades Neoplasicas</name>
      <address>
        <city>Lima</city>
        <zip>34</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Juan City Hospital</name>
      <address>
        <city>San Juan</city>
        <zip>00936-7344</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Peru</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Shennib H, Bogart J, Herndon JE, Kohman L, Keenan R, Green M, Sugarbaker D; Cancer and Leukemia Group B; Eastern Cooperative Oncology Group. Video-assisted wedge resection and local radiotherapy for peripheral lung cancer in high-risk patients: the Cancer and Leukemia Group B (CALGB) 9335, a phase II, multi-institutional cooperative group study. J Thorac Cardiovasc Surg. 2005 Apr;129(4):813-8.</citation>
    <PMID>15821648</PMID>
  </results_reference>
  <results_reference>
    <citation>Bogart J, Shennib H, Kohman L, et al.: Radiotherapy following thorascopic wedge resection (TWR) of T1 non-small cell lung cancer (NSCLC) in high risk patients: a Cancer and Leukemia Group B and Eastern Cooperative Oncology Group Phase II Trial. [Abstract] Proceedings of the American Society of Clinical Oncology 19: A1907, 2000.</citation>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 12, 2016</last_update_submitted>
  <last_update_submitted_qc>July 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I non-small cell lung cancer</keyword>
  <keyword>squamous cell lung cancer</keyword>
  <keyword>large cell lung cancer</keyword>
  <keyword>adenocarcinoma of the lung</keyword>
  <keyword>bronchoalveolar cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

